Stay updated with breaking news from Nasdaq Afmd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Affimed (NASDAQ:AFMD – Get Free Report) was the target of a significant drop in short interest during the month of April. As of April 30th, there was short interest totalling 204,100 shares, a drop of 7.0% from the April 15th total of 219,400 shares. Based on an average daily volume of 94,600 shares, the short-interest […]
Cantor Fitzgerald reissued their overweight rating on shares of Affimed (NASDAQ:AFMD – Free Report) in a report published on Monday morning, Benzinga reports. Several other analysts also recently weighed in on the stock. StockNews.com started coverage on shares of Affimed in a research report on Tuesday, January 2nd. They issued a sell rating on the […]
AFM24 combination with atezolizumab (AFM24-102): Follow-up of the Phase 1/2a combination study confirmed four responses in the non-small cell cancer...
Affimed (NASDAQ:AFMD – Get Free Report) passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $0.53 and traded as high as $0.60. Affimed shares last traded at $0.58, with a volume of 740,235 shares changing hands. Analysts Set New Price Targets AFMD has […]
StockNews.com initiated coverage on shares of Affimed (NASDAQ:AFMD – Free Report) in a research note issued to investors on Tuesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Other analysts also recently issued reports about the company. HC Wainwright restated a buy rating and issued a $5.00 price objective on shares […]